Three separate teams of physician scientists at UCLA working on three different parts of the project have made significant progress and are ready to merge their work into a complete proof-of-concept vaccine construct […]
Ultradent Products, Inc. is announcing the addition of the Ultrapro™ Tx Cordless handpiece to its prestigious Ultrapro™ Tx prophylaxis family […]
Peer-reviewed publication includes data from the CNM-Au8 Phase 2 RESCUE-ALS trial and its open-label-extension, up to 120 weeks of patient follow-up
[…]
Recursion Celebrates Opening of Its Canadian Headquarters in Toronto with Government Officials and the Biotech Ecosystem […]
Intermountain Health Opens New Outpatient Surgery Center on TOSH Campus in Murray […]
UCLA research team has successfully created 7 pre-clinical monoclonal antibody candidates for targeting Ewing sarcoma […]
On June 13, the U.S. Food and Drug Administration (FDA) issued the final guidance: Content of Premarket Submissions for Device Software Functions. The final guidance provides information regarding the recommended documentation sponsors should include in premarket submissions for the FDA’s evaluation of the safety and effectiveness of device software functions. The guidance replaces the FDA’s […]
Utah legislators on Wednesday, June 14, held a meeting of the Utah Life Sciences Innovation Caucus (ULSIC) at the state capitol. BioUtah President and CEO, Kelvyn Cullimore, kicked off the meeting and introduced representatives from Denali Therapeutics and Alucent Biomedical who presented before the ULSIC. Cindy Dunkle, chief people officer for Denali, described the company’s […]
Recursion’s small molecule is the first therapeutic candidate to be advanced to an industry-sponsored Phase 2 clinical trial for cerebral cavernous malformation (CCM). CCM is a devastating neurovascular disease with approximately 360,000 symptomatic patients in the United States and EU5. […]
Myriad to support MD Anderson researchers studying metastatic renal cell carcinoma treatment selection and response […]
Acquisitions broaden Merit’s therapeutic platform with diverse dialysis product solutions and expand its access catheter offering Acquisitions projected to add approximately $30 million of revenue, on an annualized basis, in key strategic markets that leverage existing commercial footprint Merit re-affirms full-year 2023 financial guidance on stand-alone basis and updates full-year 2023 financial guidance to include […]
SALT LAKE CITY, Utah – May 30, 2023 (OrthoSpineNews)- Kolosis BIO (Kolosis), a leading provider of biologics solutions, and MTF Biologics, a global tissue processor and nonprofit organization, are excited to announce their partnership in the surgical incision market. This strategic collaboration represents Kolosis BIO’s expansion into a new area of healthcare, while providing MTF […]